Isis Pharmaceuticals, Inc. Form 10K - page 132

F-44
First
Quarter
Second
Quarter
Third
Quarter
Fourth
Quarter
2013Quarters
...........................................................
Revenue .................................................................... $
43,360 $
38,092 $
23,585 $
42,248
Operating expenses ...................................................
41,735
46,020
49,090
62,106
Income (loss) fromoperations ..................................
1,625
(7,928)
(25,505)
(19,858)
Net loss ..................................................................... $
(1,672) $
(10,126) $
(24,570) $
(24,276)
Basic and dilutednet loss per share (1) ..................... $
(0.02) $
(0.09) $
(0.21) $
(0.21)
First
Quarter
Second
Quarter
Third
Quarter
Fourth
Quarter
2012Quarters
...........................................................
Revenue .................................................................... $
23,235 $
47,340 $
11,601 $
19,873
Operating expenses ...................................................
41,690
43,644
39,647
45,992
Income (loss) fromoperations ..................................
(18,455)
3,696
(28,046)
(26,119)
Net loss ..................................................................... $
(23,995) $
(1,207) $
(37,639) $
(2,637)
Basic and dilutednet loss per share (1) ..................... $
(0.24) $
(0.01) $
(0.37) $
(0.03)
(1)
We computednet loss per share independently for each of the quarters presented. Therefore, the sumof the quarterlynet loss
per sharewill not necessarily equal the total for the year.
I...,122,123,124,125,126,127,128,129,130,131 133,134
Powered by FlippingBook